Acceleron to Present at the 27th Annual JP Morgan Healthcare Conference

Company to introduce breakthrough program for treatment of anemia and new data from Acceleron’s innovative bone, muscle and anti-angiogenesis programs

CAMBRIDGE, Mass. – January 6, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the 27th Annual JP Morgan Healthcare Conference on Tuesday January 13, 2009 at 3:00 PM PST (6:00 PM EST) at the Westin St. Francis Hotel in San Francisco.

The presentation will highlight the breadth of Acceleron’s pipeline and the significant clinical and commercial potential of its novel drug candidates. Data will be presented on the following programs:

ACE-011 - a unique drug under development shown to increase hemoglobin and bone mass resulting in a unique profile for the treatment of cancer and non-cancer conditions. ACE-011 is currently being studied in a Phase 2 trial in multiple myeloma patients with osteolytic bone disease. ACE-011 is being jointly developed by Acceleron and Celgene Corporation
ACE-031 - the only compound under development that can concurrently increase bone and muscle mass and strength while also reduce fat mass. ACE-031 is being studied in an ongoing Phase 1 clinical trial in healthy volunteers.
ACE-041 - a non-VEGF-based anti-angiogenesis agent, expected to enter clinical trials in 2009
ACE-536 - a novel non-erythropoietin (EPO), non-hypoxia-inducible factor 1-alpha agent that increases hemoglobin, expected to enter clinical trials in 2009.

About Acceleron

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, red blood cells, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the Growth and Differentiation Factor (GDF) family of proteins. ACE-011 is currently being studied in a Phase 2 clinical trial in multiple myeloma patients with osteolytic bone disease. ACE-031 is currently being studied in a Phase 1 clinical trial in healthy volunteers. In addition, the company is advancing new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase hemoglobin. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Bessemer Ventures, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com.

CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development

Paul Kidwell (Media)
Suda Communications LLC, tel: 617-296-3854

BACK TO PRESS RELEASES